Pliant Therapeutics Pivots to Oncology, Highlights Early PLN-101095 Responses at Oppenheimer Conference [Yahoo! Finance]
Pliant Therapeutics, Inc. (PLRX)
Company Research
Source: Yahoo! Finance
company, advancing internal oncology programs and a targeted siRNA delivery platform while evaluating potential in-licensing or acquisition opportunities. Early Phase I data for oral PLN-101095 (avß8/avß1 inhibitor) showed activity at =1,000 mg BID with four clinical responders (three PRs, one CR across four tumor types), an average tumor reduction of ~71% among responders, and generally manageable safety (most common AE: mild–moderate rash). Pliant plans a Phase Ib dose-expansion with pembrolizumab (first patient expected in Q2) across selected cohorts (NSCLC, high TMB, RCC), expects oncology data next year, and reported approximately $211 million pro forma cash supporting a runway into at least H2 2028. Interested in Pliant Therapeutics, Inc.? Here are five stocks we like better. Pliant Therapeutics Gaps 34% Higher: More Upside To Come? Pliant Therapeutics (NASDAQ:PLRX) used its presentation at Oppenheimer's 36th Annual Healthcare Conference to outline its strategic transi
Show less
Read more
Impact Snapshot
Event Time:
PLRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLRX alerts
High impacting Pliant Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PLRX
Earnings
- 11/6/25 - Beat
PLRX
Sec Filings
- 3/3/26 - Form 8-K
- 2/17/26 - Form SCHEDULE
- 2/17/26 - Form SCHEDULE
- PLRX's page on the SEC website